11.5 C
New York
Wednesday, February 8, 2023

Agile Therapeutics Inc. (AGRX) Is Not Likely To Be The Same Tomorrow

After Hours

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. After-hours trades for Agile Therapeutics Inc. (AGRX) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.0083, or 3.83%, to $0.225. The Agile Therapeutics Inc. has recorded 12,368 volume in the after hours trading session. Recently, Yahoo Finance discussed the stock, revealing that This Biotech Company is Pursuing Positive Cash Flow In 2023.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Stocks Info

Agile Therapeutics Inc. is listed on the NASDAQ in the Healthcare sector while operating in the Drug Manufacturers – Specialty & Generic industry. At the end of the last regular session, the stock closed at $0.22 and fluctuated between $0.2400 as its day high and $0.2128 as its day low. The current market capitalization of Agile Therapeutics Inc. is $7.73M. A total of 0.79 million shares were traded on the day, compared to an average of 833.92K shares.

Insider trades are also considered as indicators of how a stock will perform in the future, in addition to stock predictions. During the recent three months, AGRX has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 8 BUYs and 0 SELLs from insiders. Insiders purchased 54,690 shares during that period but sold 0.

In the most recent transaction, ALTOMARI ALFRED bought 50,000 shares of AGRX for 0.45 per share on Aug 26. After the transaction, the Chief Executive Officer now owns 64,343 company shares.

Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. According to analysts who have offered 12-month price targets for AGRX in the last 3 months, the mean price target is $2.00 with high estimates of $3.00 and low estimates of $1.00. In terms of 52-week highs and lows, AGRX has a high of $21.34 and a low of $0.17.

As of this writing, AGRX has an earnings estimate of -$0.29 per share for the current quarter. EPS was calculated based on a consensus of 2 estimates, with a high estimate of -$0.29 per share and a lower estimate of -$0.3. The company reported an EPS of -$8 in the last quarter, which was -33.30% lower than expectations of -$6.

Balance Sheet Annually/Quarterly

As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information.

Analysts Opinion

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 2 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for AGRX is Buy with a score of 5.00. A total of 2 analysts rated the stock as Buy while 0 rated it as Overweight while 0 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles